growth stock

Axon posted a disasterous loss of U.S$10m last calendar year.

Its shareholder update of December 2002 said they would inititate R&D constraints and shed some staff to save U.S$4M in this calender year.

Well, by simple arithmetic, Axon was still staring at a U.S$6m deficit.

The only way that they could be running at breakeven, as disclosed in their response to the stock exchange today, is if they have posted a pretty impressive growth in sales.

Break even is boring, but growth, especially at this low market cap, is attractive.